# Candel Therapeutics, Inc. (CADL): Analyst Consensus Highlights 238.64% Potential Upside for Cancer-Focused Biotech

- Link: https://www.directorstalkinterviews.com/candel-therapeutics-inc-cadl-analyst-consensus-highlights-238-64-potential-upside-for-cancer-focused-biotech/4121231170
- Published: 2025-12-18T11:35:32+00:00
- Author: Madison Wilson

In the fast-evolving world of biotechnology, Candel Therapeutics, Inc. (NASDAQ: 
CADL) stands out as a promising player with a strong focus on developing innovative
cancer immunotherapies. Headquartered in Needham, Massachusetts, Candel Therapeutics
operates within the healthcare sector, specifically the biotechnology industry. 
It is a clinical-stage biopharmaceutical company that is capturing investor attention
with a market capitalization of approximately $301.94 million.

Candel Therapeutics’ current stock price is $5.50, showing a slight dip with a recent
price change of -0.24 (-0.04%). Despite this minor setback, the stock’s 52-week 
range is a testament to its volatility and potential, spanning from $4.39 to $12.21.
Investors looking for growth opportunities should note the significant potential
upside of 238.64%, based on the average analyst target price of $18.63. This optimism
is reflected in the analyst ratings, with seven buy ratings and just one hold, suggesting
strong confidence in the company’s prospects.

The company’s flagship products include CAN-2409 and CAN-3110, both of which are
undergoing various phases of clinical trials aimed at treating different types of
cancer. CAN-2409 is in Phase III trials for prostate cancer and Phase II trials 
for pancreatic cancer and non-small cell lung cancer (NSCLC), while CAN-3110 is 
in Phase Ib trials targeting recurrent high-grade glioma. Candel also boasts the
enLIGHTEN Discovery Platform, which leverages herpes simplex virus-based technology
to develop new viral immunotherapies for solid tumors.

Despite these promising developments, Candel Therapeutics faces typical financial
challenges associated with clinical-stage biotech firms. The company’s financial
metrics reveal ongoing investment in R&D and clinical trials, with a notable EPS
of -0.56 and a return on equity of -70.17%. Free cash flow stands at -$21,153,500,
reflecting the capital-intensive nature of its operations. Furthermore, the forward
P/E ratio is -11.00, underscoring the absence of immediate profitability.

From a technical standpoint, Candel’s momentum is indicated by a 50-day moving average
of $5.29 and a 200-day moving average of $5.66. The Relative Strength Index (RSI)
of 58.60 suggests the stock is neither overbought nor oversold, while the MACD and
signal line values of 0.24 and 0.15, respectively, signal a bullish trend.

While Candel Therapeutics does not currently offer dividends, the company’s strategic
focus on pioneering cancer treatments could yield substantial long-term returns 
for investors willing to embrace the inherent risks of biotech investments. The 
analyst consensus and the significant potential upside present a compelling narrative
for those seeking exposure to the cutting-edge of cancer treatment innovation. As
always, investors should consider their risk tolerance and conduct thorough due 
diligence before taking a position in this promising biotech entity.

Share on: